Medibio Limited
Medibio Limited (MEB.AX) Stock Overview
Explore Medibio Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
4.5M
P/E Ratio
0.00
EPS (TTM)
$-0.01
ROE
-0.47%
MEB.AX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Medibio Limited (MEB.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.01.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.00 and a market capitalization of 4.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Medibio Limited, a health technology company, assists in the detection and screening of mental health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is headquartered in Melbourne, Australia.
Thomas R. Young
4
100 Albert Road, Melbourne, VIC
2001